Table 3 Clinicopathologic characteristics of septic patients with genetic variants in the prolyl-hydroxlase 2 gene (SNP rs480902)

Patients characteristics

 Gender (women/men; %)

23/49 (31.9/68.1)

14/30 (31.8/68.2)

7/5 (58.3/41.7)

0.185**

 age (years; median; Q1; Q3)^b

58 (45–70)

54.5 (46–65)

67 (55–78)

0.111*

 height (cm; median; Q1; Q3)^b

174 (165–180)

178 (169–182)

165 (160–175)

0.122*

 body weight (kg; median; Q1; Q3)^b

80 (70–90)

85 (65–96)

80 (70–86)

0.455*

 BMI (kg/m²; median; Q1; Q3)^b

26.2 (22.9–30.5)

27.8 (22.8–33)

27.8 (24–30.8)

0.759*

 Heart rate (min⁻¹; median, Q1; Q3)^b

101 (92–124)

110 (92–135)

96 (72–125)

0.753*

 Mean arterial blood pressure (mmHg; median; Q1; Q3)^b

76 (63–88)

73 (63–87)

70 (54–87)

0.484*

 creatinin serum concentration (mg dl⁻¹; (median; Q1;Q3)^b

1.45 (1.0–3.0)

1.48 (1.0–2.1)

1.95 (1.0–2.4)

0.506*

 Dialysis (yes/no; %)

48/23 (67.6/32.4)

30/14 (68.2/31.8)

6/6 (50/50)

0.468**

Primary diagnoses %

 Cardiovascular disease

4 (6.5)

5 (13.2)

1 (10)

^c

 Hematooncological disease

4 (6.5)

2 (5.3)

1 (10)

 Gastrointestinal disease

22 (35.5)

10 (26.3)

5 (50)

 Lung disease

13 (20.9)

12 (31.5)

1 (10)

 Urogenital cancer

6 (9.7)

2 (5.3)

0

 Intraabdominal pathology, other Cancer, other

13 (20.9)

7 (18.4)

5 (20)

Infectious variables

 White blood cell count (10⁹ l⁻¹; median; Q1; Q3)^b

15.0 (9.7–20.9)

12.1 (8.1–18.3)

12.3 (8.9–21.2)

0.632*

 Procalcitonin concentration (μg l⁻¹; median; Q1; Q3)^b

3.6 (1.0–22.2)

3.5 (1.0–11.5)

14.9 (0.7–18.7)

0.789*

 C-reactive protein concentration (g l⁻¹; median; Q1; Q3)^b

17.2 (8.6–23.9)

15.2 (9.7–24.7)

22.9 (7.2–39.4)

0.155*

Disease severity

 SAPS II^d (mean ± SD)^a

37 (29–45)

37 (27–49)

37 (25–51)

0.941*

 Hospital stay (d; mean ± SD)^a

26 (10–44)

17 (12–31)

23 (12–33)

0.121*

 30-day mortality (%)

27 (37.5)

18 (40.9)

4 (33.3)

0.876**